The abstract is read at the publisher; the summary is JClub's.
A GalNAc-conjugated C5-targeted siRNA shows picomolar in vitro potency (IC 50 = 0.013 nM) and sustained C5 suppression in cynomolgus non-human primates with >80% for 2 months.
- Why it matters: IgA nephropathy involves excessive complement activation, yet clinically efficacious complement-targeted therapies remain scarce.
- What they did: The study profiled a N-acetylgalactosamine-conjugated small interfering RNA against complement component 5, testing inhibitory activity in vitro and durability after a single subcutaneous dose in cynomolgus monkeys.
- The result: In a cynomolgus monkey IgAN model, C5-siRNA produced comparable renal function improvements to Nefecon but achieved superior pathological remission with near-complete blockade of glomerular C5 deposition and membrane attack complex formation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.